As the U.S. economy restarts and retools after the forced shutdown induced by the Covid-19 pandemic, there is a strong drive in Congress and the executive branch to improve the resilience of medical supply chains. The Covid-19 pandemic caused an unprecedented demand for certain medical goods, including pharmaceuticals, personal protective equipment, and medical devices. Manufacturers in the medical supply sector, the U.S. government, and foreign governments are likely to embrace new policies aimed at readjusting global supply chains to address vulnerabilities that have come to light.
CSIS research has focused on approaches to building medical supply chain resiliency through diversification, trust, and communication. Just as the pandemic revealed vulnerabilities in global supply chains, it also proved that no single country can produce all that it needs to fight Covid-19, let alone cure it. These changing circumstances present a new opportunity for the United States to reinvigorate trade relations with allies, free trade agreement partners, and trusted supplier countries as partners. We recommend the trusted partner model as a preferred alternative to relying on reshoring.
We are honored to have Tim Manning, Supply Coordinator for the White House Covid-19 Response Team, join us as a keynote speaker. Our distinguished panelists include John Murphy, Senior Vice President for International Policy at the U.S. Chamber of Commerce; Abby Pratt, Covid-19 Supply Chain Lead and Vice President for Global Strategy and Analysis at AdvaMed; and Jeffrey Weiss, Partner at Steptoe.
This event is made possible through the generous support of Gilead Sciences, Inc.; Pfizer, Inc.; and the U.S. Chamber of Commerce.
